|
The recent update to the
European Commission Initiative on Breast Cancer (ECIBC) guidelines, published in 2021, recommends digital breast tomosynthesis (DBT) for women with high mammographic breast density.1
Almost 50% of women over 40 have dense breast tissue that can obscure lesions on traditional 2D mammograms, making cancers harder to detect and recalls more likely.2
Women with very dense breasts are also at four to five times greater risk of developing breast cancer than women with less dense
breasts.2 Identifying these women would mean they could be prioritised for more frequent or personalised screening.
However, in many countries there are no official requirements for systematic breast density assessments, making this hard to do.
THE ROLE OF IMAGING TECHNOLOGY AND AI SOLUTIONS
Technology has a key role to play in supporting personalised screening. Hologic's 3D Mammography™ exam has revolutionised breast cancer detection with better, earlier breast cancer detection for women of all ages and breast densities. Studies have shown that Hologic 3D Mammography finds up to 65% more invasive breast cancers compared to 2D mammography alone.3
It is the only mammogram approved in the USA by the FDA as superior to standard 2D mammography for routine breast cancer screening in dense breasts.4
Breast density assessment tools can also help
with standardising classification
Hologic's Quantra™ 2.2 uses a machine learning algorithm to analyse each woman's individual breast pattern and texture, providing unbiased breast density assessment in line with the ACR BIRADS® Atlas Fifth Edition classifications. This removes any potential for visual subjectivity.
Explore our scientific webinar series to learn more:
To learn more about Hologic's technologies and AI solutions:
Hologic BV, Da Vincilaan 5, 1930 Zaventem, Belgium
References
1. European Commission. European Breast Cancer Guidelines: Women with high breast density. https://healthcare-quality.jrc.ec.europa.eu/european-breast-cancer-guidelines/dense-breast Accessed 12.2.22
2. Sprague BL, Gangnon RE, Burt V, et al. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst. 106(10),
2014. 3. Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital
mammography." JAMA 311.24 (2014): 2499-2507 4. Food & Drug Administration Premarket Approval (PMA). FDA.gov
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P080003S005 accessed June 5, 2017. EMB-01870-EUR-EN Rev 001. ©2022 Hologic, Inc. All rights reserved. Hologic, 3Dimensions, 3DQuorum, Clarity HD, Quantra, and associated
logos are trademarks or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other
trademarks, registered trademarks and product names are the property of their respective owners. This information is intended for medical
professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are
distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For information on
specific products available for sale
in a particular country, please contact your Hologic representative or write to euinfo@hologic.com
|
AuntMinnieEurope.com, 671 N Glebe Road, Suite #1610, Arlington, VA 22203 USA
+1 520-298-1000
|
|
